Physician profile
Ashlee O'Shell
NPI 1912357526
$802.18
in general payments reported to CMS, 2019-2025
12 companies · $169 in 2025
The $169 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.14 · 2022: $90.65 · 2023: $306 · 2024: $185 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $156.02 | 2024-2025 | Zurzuvae |
| Gynesonics, INC. | $153.15 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Mayne Pharma Commercial LLC | $98.79 | 2022-2024 | |
| Evofem Biosciences, INC. | $60.67 | 2021-2022 | |
| Abbvie INC. | $60.23 | 2022-2023 | |
| Astellas Pharma US INC | $57.56 | 2023-2025 | Veozah |
| Millicent US INC | $43.77 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Smith+Nephew, INC. | $41.22 | 2023-2024 | Grafix Pl, Stravix Pl |
| Coopersurgical, INC. | $40.56 | 2022-2024 | Paragard T 380a |
| Shield Therapeutics INC | $36.44 | 2023-2024 | Accrufer |
| Amgen INC. | $33.09 | 2021-2023 | Prolia, Evenity |
| Organon LLC | $20.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlee O'Shell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.